Video

TAK-700 in Localized Prostate Cancer Clinical Trials

Author(s):

Howard M. Sandler, MD

Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses the examination of hormonal and radiation therapy used in combination for localized prostate cancer. A new agent named TAK-700 is being examined in multiple studies for various types of prostate cancer.

Related Videos
Rupesh Rajesh Kotecha, MD
David A. Braun, MD, PhD
Francine Foss, MD
Daniel E. Haggstrom, MD
Ami Umesh Badami, MD
Kenneth Shain, MD, PhD
Piotr Rutkowski, MD
Manali Kamdar, MD, of University of Colorado Anschutz School of Medicine
Janaki Neela Sharma, MD, assistant professor, clinical medicine, Genitourinary Medical Oncology, University of Miami Health Systems
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Related Content
Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute; professor, medicine, University of Utah
October 31st 2024

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Oliver Sartor, MD
October 23rd 2024

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

James Breitmeyer, MD, PhD
October 22nd 2024

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC